Clinical trial process
RITI® RA

A clinical trial is underway to demonstrate the efficacy of the RITI® RA test, a test that helps with the prescription of biotherapies in the treatment of rheumatoid arthritis

From a patient’s blood sample, the RITI® RA test is able to generate an efficacy score for each biotherapy depending on the patient’s biology. The physician can also direct their prescription to the biopharmaceutical that will maximize the chances of achieving remission.

After having recently validated the CE marking, a clinical trial is underway involving 234 patients and aims to show the relevance of the RITI® RA test in the treatment of rheumatoid arthritis. The last major step before marketing the innovation is currently planned for 2025.

The clinical study in figures

0
university or general hospitals across mainland France
0
patients included
0
month study duration

Clinical trial process

Our scientific study follows a strict process and the protocol has been validated by the French National Authority for Health.

Inclusion visit (D-30 to D0)

The inclusion visits take place during routine visits to the rheumatology department at the hospitals included in the clinical trial. The investigator verifies whether the patient meets the inclusion criteria and obtains their consent before prescribing them the biotherapy of their choice.

RITI® RA Test

The investigator takes a blood sample from the patient in order to analyze the transcriptome to create the RITI® RA report.

Final visit (D180)

Final visit: The investigator collects the information needed to calculate the DAS28 using a questionnaire, then assesses whether to continue with or stop the biotherapy that was prescribed previously. The investigator receives the results of the patient’s RITI® RA report and compares it with their patient’s condition after the biotherapy that they prescribed. The investigator gives their opinion regarding RITI® RA using a specific questionnaire.

be informed

on publication of the trial results